Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From Its Majority Stockholder

Cornerstone Therapeutics Inc. Announces Receipt of Take-Private Proposal From 
Its Majority Stockholder 
CARY, NC -- (Marketwire) -- 02/20/13 --  Cornerstone Therapeutics
Inc. (NASDAQ: CRTX) (the "Company") announced today that its Board of
Directors has received a letter from Chiesi Farmaceutici SpA
("Chiesi"). In that letter Chiesi, which owns approximately 60% of
the outstanding shares of the Company's common stock, made a
proposal, subject to certain conditions, to acquire the shares of the
Company's common stock that it does not already own for a cash
purchase price of between $6.40 and $6.70 per share.  
The text of Chiesi's letter will be filed as an exhibit to a Report
on Form 8-K to be filed today by the Company with the SEC. 
The Company cautions its stockholders and others considering trading
in its common stock that no decisions have been made by the Board of
Directors with respect to Chiesi's proposal. There can be no
assurance that any agreement will result from the proposal submitted
by Chiesi or that any transaction based on Chiesi's proposal will be
consummated. 
About Cornerstone Therapeutics 
Cornerstone Therapeutics Inc. (NASDAQ: CRTX), headquartered in Cary,
N.C., is a specialty pharmaceutical company focused on
commercializing products for the hospital and adjacent specialty
markets. Key elements of the Company's strategy are to focus its
commercial and development efforts in the hospital and adjacent
specialty product sector within the U.S. pharmaceutical marketplace;
continue to seek out opportunities to acquire companies, marketed or
registration-stage products and late-stage development products that
fit within the Company's focus areas; and generate revenues by
marketing approved generic products through the Company's
wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. For more
information, visit www.crtx.com. 
Contacts  
Investor Relations Contact: 
Josh Franklin
Vice President, Strategy and Business Development
+1-919-678-6520
josh.franklin@crtx.com 
 
 
Press spacebar to pause and continue. Press esc to stop.